Seattle Genetics, Inc. today announced that Health Canada has issued a Notice of Compliance with conditions , authorizing marketing of ADCETRIS for two lymphoma indications: the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant or after failure of at least two multi-agent chemotherapy regimens in patients ... (more)
http://www.biospace.com/news_story.aspx?StoryID=286515&full=1
http://www.biospace.com/news_story.aspx?StoryID=286515&full=1
No comments:
Post a Comment